185 related articles for article (PubMed ID: 30622981)
1. An O-Antigen Glycoconjugate Vaccine Produced Using Protein Glycan Coupling Technology Is Protective in an Inhalational Rat Model of Tularemia.
Marshall LE; Nelson M; Davies CH; Whelan AO; Jenner DC; Moule MG; Denman C; Cuccui J; Atkins TP; Wren BW; Prior JL
J Immunol Res; 2018; 2018():8087916. PubMed ID: 30622981
[TBL] [Abstract][Full Text] [Related]
2. Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis.
Cuccui J; Thomas RM; Moule MG; D'Elia RV; Laws TR; Mills DC; Williamson D; Atkins TP; Prior JL; Wren BW
Open Biol; 2013 May; 3(5):130002. PubMed ID: 23697804
[TBL] [Abstract][Full Text] [Related]
3. Glycoconjugate vaccine using a genetically modified O antigen induces protective antibodies to
Stefanetti G; Okan N; Fink A; Gardner E; Kasper DL
Proc Natl Acad Sci U S A; 2019 Apr; 116(14):7062-7070. PubMed ID: 30872471
[No Abstract] [Full Text] [Related]
4. A glucan-particle based tularemia subunit vaccine induces T-cell immunity and affords partial protection in an inhalation rat infection model.
Whelan AO; Flick-Smith HC; Walker NJ; Abraham A; Levitz SM; Ostroff GR; Oyston PCF
PLoS One; 2024; 19(5):e0294998. PubMed ID: 38713688
[TBL] [Abstract][Full Text] [Related]
5. The rLVS Δ
Mlynek KD; Cline CR; Biryukov SS; Toothman RG; Bachert BA; Klimko CP; Shoe JL; Hunter M; Hedrick ZM; Dankmeyer JL; Mou S; Fetterer DP; Qiu J; Lee ED; Cote CK; Jia Q; Horwitz MA; Bozue JA
Hum Vaccin Immunother; 2023 Dec; 19(3):2277083. PubMed ID: 37975637
[No Abstract] [Full Text] [Related]
6. Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies.
Chen L; Valentine JL; Huang CJ; Endicott CE; Moeller TD; Rasmussen JA; Fletcher JR; Boll JM; Rosenthal JA; Dobruchowska J; Wang Z; Heiss C; Azadi P; Putnam D; Trent MS; Jones BD; DeLisa MP
Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3609-18. PubMed ID: 27274048
[TBL] [Abstract][Full Text] [Related]
7. Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.
Richard K; Mann BJ; Stocker L; Barry EM; Qin A; Cole LE; Hurley MT; Ernst RK; Michalek SM; Stein DC; Deshong P; Vogel SN
Clin Vaccine Immunol; 2014 Feb; 21(2):212-26. PubMed ID: 24351755
[TBL] [Abstract][Full Text] [Related]
8. Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.
Richard K; Mann BJ; Qin A; Barry EM; Ernst RK; Vogel SN
Clin Vaccine Immunol; 2017 Mar; 24(3):. PubMed ID: 28077440
[No Abstract] [Full Text] [Related]
9. Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains.
Wu TH; Zsemlye JL; Statom GL; Hutt JA; Schrader RM; Scrymgeour AA; Lyons CR
Vaccine; 2009 Jul; 27(34):4684-93. PubMed ID: 19520198
[TBL] [Abstract][Full Text] [Related]
10. A ΔclpB mutant of Francisella tularensis subspecies holarctica strain, FSC200, is a more effective live vaccine than F. tularensis LVS in a mouse respiratory challenge model of tularemia.
Golovliov I; Twine SM; Shen H; Sjostedt A; Conlan W
PLoS One; 2013; 8(11):e78671. PubMed ID: 24236032
[TBL] [Abstract][Full Text] [Related]
11. Protection induced by a Francisella tularensis subunit vaccine delivered by glucan particles.
Whelan AO; Flick-Smith HC; Homan J; Shen ZT; Carpenter Z; Khoshkenar P; Abraham A; Walker NJ; Levitz SM; Ostroff GR; Oyston PCF
PLoS One; 2018; 13(10):e0200213. PubMed ID: 30296254
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Francisella tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model.
Tian D; Uda A; Park ES; Hotta A; Fujita O; Yamada A; Hirayama K; Hotta K; Koyama Y; Azaki M; Morikawa S
Microbiol Immunol; 2018 Jan; 62(1):24-33. PubMed ID: 29171073
[TBL] [Abstract][Full Text] [Related]
13. Live attenuated Francisella novicida vaccine protects against Francisella tularensis pulmonary challenge in rats and non-human primates.
Chu P; Cunningham AL; Yu JJ; Nguyen JQ; Barker JR; Lyons CR; Wilder J; Valderas M; Sherwood RL; Arulanandam BP; Klose KE
PLoS Pathog; 2014 Oct; 10(10):e1004439. PubMed ID: 25340543
[TBL] [Abstract][Full Text] [Related]
14. Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia.
Hickey AJ; Hazlett KR; Kirimanjeswara GS; Metzger DW
Vaccine; 2011 Sep; 29(40):6941-7. PubMed ID: 21803089
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Schu S4
Cunningham AL; Mann BJ; Qin A; Santiago AE; Grassel C; Lipsky M; Vogel SN; Barry EM
Virulence; 2020 Dec; 11(1):283-294. PubMed ID: 32241221
[TBL] [Abstract][Full Text] [Related]
16. Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A.
Wu TH; Hutt JA; Garrison KA; Berliba LS; Zhou Y; Lyons CR
Infect Immun; 2005 May; 73(5):2644-54. PubMed ID: 15845466
[TBL] [Abstract][Full Text] [Related]
17. BALB/c mice, but not C57BL/6 mice immunized with a ΔclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge immune responses.
Twine S; Shen H; Harris G; Chen W; Sjostedt A; Ryden P; Conlan W
Vaccine; 2012 May; 30(24):3634-45. PubMed ID: 22484348
[TBL] [Abstract][Full Text] [Related]
18. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.
Jia Q; Lee BY; Bowen R; Dillon BJ; Som SM; Horwitz MA
Infect Immun; 2010 Oct; 78(10):4341-55. PubMed ID: 20643859
[TBL] [Abstract][Full Text] [Related]
19. Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain.
Reed DS; Smith LP; Cole KS; Santiago AE; Mann BJ; Barry EM
Infect Immun; 2014 May; 82(5):2098-105. PubMed ID: 24614653
[TBL] [Abstract][Full Text] [Related]
20. Correlates of protection following vaccination of mice with gene deletion mutants of Francisella tularensis subspecies tularensis strain, SCHU S4 that elicit varying degrees of immunity to systemic and respiratory challenge with wild-type bacteria.
Ryden P; Twine S; Shen H; Harris G; Chen W; Sjostedt A; Conlan W
Mol Immunol; 2013 May; 54(1):58-67. PubMed ID: 23201853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
